China’s Greater Bay Area: Living up to the Hype?
A decade on from its launch, the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) initiative has made some significant wins but remains some way from fulfilling the vision of a fully…
Address: 20th Floor, NCPC Building (Grand Milea Hotel), No.56 North Tiyu Street, Shijiazhuang, Hebei, P.R.China, Post Code: 050015
Tel: +86 311 85992911
Web: http://www.ncpc.com/
North China Pharmaceutical Group Corp. (NCPC) is a leading pharmaceutical manufacturer in China. NCPC in its early days was one of the key construction projects during the Chinese First Five-Year Plan. After five years of construction beginning in June 1953, operation commenced in June 1958. Being one of the world leading antibiotic producers both in technology and production scale at that time, NCPC has a history of commercial production of antibiotics in China. With 45 years of development, NCPC has been continually growing and taking the lead in China pharmaceutical industry in key economic indexes, ranking as one of the Top 500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets were USD2 billion, and the company was employing 18500 staff. In 2002, NCPC achieved domestic sales revenue USD 700million and export sales USD100million. Sticking to the spirit of ‘Service for Life ‘, NCPC aims to build bright future for all the people.
Antibiotics, Immunosuppressants
A decade on from its launch, the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) initiative has made some significant wins but remains some way from fulfilling the vision of a fully…
Writing in the September 2023 edition of DIA’s Global Forum magazine, Shuting Li of Anhui Jimin Cancer Hospital and Xinfang Fan of Bayer Health Care Ltd. examine how Chinese clinical…
Ongoing geopolitical tensions between China and the West have led the G7 group of countries to warn of the threat of “economic coercion” from China and the US to scrutinise…
A roundup of some of the latest healthcare and pharma news from China including a crackdown on healthcare corruption; AstraZeneca’s cardiovascular mortality drug approval and mRNA manufacturing deal with CanSino;…
Writing in the August edition of DIA’s Global Forum magazine, Wen Yin of the Pfizer China R&D Center and Wanhe Deng of GSK China Investment look back on four years…
At a time when the country’s economy has fallen into a slump with the currency sinking to its lowest level in 16 years, Chinese giant Fosun Pharma continues to agressively…
A roundup of some of the biggest recent stories coming out of China, including the commerce minister’s peace offering to international drug companies; CSPC Pharmaceutical Group’s partnership with Pfizer; Merck’s…
A roundup of some of the most significant recent stories from the Chinese pharmaceutical industry, including a slate of international investment which seems to suggest that – despite ongoing political…
Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of…
The latest healthcare and life sciences news from China, including Eisai’s USD 2 billion oncology deal with Bliss Biopharma; Hasten Biopharmaceutic acquisition of commercial rights in China for Rocephin from…
China has made major healthcare strides over the past decade with regulatory reforms, infrastructure improvements, and the advancement of universal healthcare. While the COVID-19 pandemic revealed the need for further…
The latest news from the Chinese healthcare and life sciences industry, including the first public comments from Astellas CEO Naoki Okamura following an employee’s arrest on espionage charges in China,…
See our Cookie Privacy Policy Here
